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Background: Human leukocyte antigen (HLA) is a group of genes that are extremely polymorphic among
individuals and populations and have been associated with more than 100 different diseases and adverse drug
effects. HLA typing is accordingly an important tool in clinical application, medical research, and population
genetics. We have previously developed a phase-defined HLA gene sequencing method using MiSeq sequencing.
Results: Here we report a simple, high-throughput, and cost-effective sequencing method that includes normalized
library preparation and adjustment of DNA molar concentration. We applied long-range PCR to amplify HLA-B for
96 samples followed by transposase-based library construction and multiplex sequencing with the MiSeq sequencer.
After sequencing, we observed low variation in read percentages (0.2% to 1.55%) among the 96 demultiplexed
samples. On this basis, all the samples were amenable to haplotype phasing using our phase-defined sequencing
method. In our study, a sequencing depth of 800x was necessary and sufficient to achieve full phasing of HLA-B
alleles with reliable assignment of the allelic sequence to the 8 digit level.
Conclusions: Our HLA sequencing method optimized for 96 multiplexing samples is highly time effective and cost
effective and is especially suitable for automated multi-sample library preparation and sequencing.
Keywords: HLA, Next-generation sequencingBackground
To date, several high-throughput HLA typing methods
using next-generation sequencing (NGS) have been devel-
oped [1-8]. In our previous study, we completely sequenced
long-range PCR amplicons encompassing entire regions of
each of the HLA genes (HLA-A, −C, −B, −DRB1, −DQB1,
and -DPB1). PCR amplicons were subjected to transposase-
based library construction and multiplex sequencing with
the MiSeq sequencer. Paired-end reads of 2 × 300 bp en-
abled us to demonstrate phase-defined allele determination
(also defined as HLA gene haplotypes) in 33 HLA homo-
zygous samples, 11 HLA heterozygous samples, and 3 par-
ent–child families. Our sequencing protocol and pipeline
provided essentially complete phase-defined HLA gene
sequences; however, it required complicated and labor-
intensive workflows especially in the library preparation* Correspondence: itinoue@nig.ac.jp
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article, unless otherwise stated.step. Most importantly, the method is not well adapted
for processing multiple samples. In the present study,
we developed a new library preparation method for
NGS and applied it to 96 samples. Long-range PCR
products of HLA-B spanning from promoters to 3′-
UTRs were prepared and sequenced with the MiSeq se-
quencer via transposase-based library preparation. In
the previous protocol, although the DNA amount of
each library was strictly measured and the library size
was validated using a BioAnalyzer before the sequen-
cing step, it was difficult to equalize the DNA amount
and molecular size of the libraries, resulting in variable
numbers of reads in each sample. We observed dropouts
of samples owing to insufficient reads. Here, we developed
a Bead-based Normalization for Uniform Sequencing
(BeNUS) procedure using three steps of bead purification.
BeNUS can easily and precisely normalize the molar con-
centrations of up to 96 samples, not only simplifying the
library preparation step but also permitting automation of
HLA typing using NGS.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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PCR amplification of HLA-B and library preparation
We applied long-range PCR to amplify HLA-B, which is
known to be highly polymorphic. HLA-B-specific ampli-
fication products were obtained from 96 individuals. All
96 PCR amplicons were subjected to transposase-based
library construction using the Nextera kit, which simul-
taneously fragments the DNA and adds adaptors needed
for multiplex sequencing. We developed protocol steps
using altered AMPure XP beads to normalize the molar
concentrations of 96 samples. Each PCR amplicon was
subjected separately to transposase-based library con-
struction, whereby a sample-specific index was intro-
duced. The Nextera kit can construct libraries of a broad
size range. For phase-defined HLA sequencing, a library
range of 500–1,000 bp is desirable. In the previous
protocol [1], the library size selection was achieved by
cutting of agarose gel and checking using a BioAnalyzer,
which is a very laborious step, especially for preparing
multiple samples.
Our new method, BeNUS, which is described in detail
in the Methods section, circumvents the gel cutting
method and employs bead-based steps for library size se-
lection as well as equalization of DNA molar concentra-
tions in up to 96 samples. More specifically, three bead
steps were performed: first, 20 μl of altered beads sus-
pended in 20% PEG and 2.5 M NaCl solution was added
to 50 μl of diluted PCR product, and the supernatant frac-
tion containing the desired fragments (<1,000 bp) was col-
lected. Second, 5 μl of beads was added to the collected
supernatant. Desired fragments of larger than 500 bp were
bound to the beads, while smaller fragments remaining in
the supernatant were discarded (Figure 1). After these two
steps, the desired DNA fragments (500–1,000 bp) were se-
lected (actual size: 492 to 1,625 bp, average size: 924 bp)
(Additional file 1: Figure S1). Finally, 20-fold diluted beads
were added to the size-fractionated library. Small numbers
of beads can bind saturated amounts of DNA because
bound DNA is in proportion to the number of beads
(Additional file 2: Figure S2). Eventually, the final DNA
size, concentration, and thereby molar concentration were
equalized (Additional file 3: Figure S3).
Complete sequencing of HLA-B for 96 samples
The Nextera-treated libraries from 96 HLA-B PCR ampli-
cons were subjected to NGS sequencing. The distribution
of reads among the 96 multiplexed indexes ranged from
0.2% to 1.55% as percentages of 24.6 million reads and
1.04 ± 0.32% on average. Technical improvements in li-
braries preparation were clarified by comparison between
our previous method, cutting of agarose gel followed by
the BioAnalyzer, and BeNUS method. The distribution of
respective read numbers by the previous method was
0.06% to 2.74% and the value by BeNUS method was 0.2to 1.55% (Figure 2). Sequence reads of HLA-B, were
aligned to the reference sequence at an average mapped
rate of 99.63%, ranging from 99.11 to 99.87%. The average
depth of the alignment before phasing was 6495.3× and
the phased haplotype depth was 2097.8×. Of the 96 sam-
ples, heterozygous SNVs and indels were not observed in
8 samples (0605, 0607, 0645, 1057, 1169, 1184, 1199, and
1229) indicating completely homozygous haplotypes. Gen-
erally, MiSeq yields base errors at a rate of 0.8% with PCR
free library preparation [9]. In the result of these homozy-
gous samples, the total error rate of sequencing reaction
and PCR amplification was estimated to be as less than
1.2%. In our simulated alignment result, the maximum
error rates in 300× and 200× average depth were 4.8% and
6%, respectively, and the minimum depth for complete
phasing was approximately 800× average depth. We
recognize phasing result is not only dependent on average
depth but also on distance between two heterozygous
SNVs and long insert library covering the two heterozy-
gous SNVs. As a general method, we propose that se-
quence reads of at least 800× depth is valid for providing
the phase-defined HLA sequences with for high accuracy
(less than 5% error rate). All samples were completely
phased by the phase-defined sequencing pipeline [1], al-
though six samples showed only 1 to 7 SNVs in one exon:
samples 0785, 1018, 1117, and 1175 had 4, 7, 3, and 3 het-
erozygous SNVs in exon 2, respectively. Sample 1224 had
3 heterozygous SNVs in exon 3, whereas sample 0979 had
one heterozygous SNV in exon 5 (Figure 3). All the above
samples were also phased using partial phasing (Additional
file 4: Figure S4). Allelic imbalance as a result of PCR is
manifested by skewed allelic calls after HLA sequencing.
Allelic imbalance of the PCR amplification of HLA-B was
negligible, as judged by the ratio of sequencing depth be-
tween the two phased alignments; 1:1.68 at the maximum
and 1:1.19 on average in heterozygous samples (Table 1).
Consequently, 192 haplotype sequences of 96 individuals,
which include 28 different haplotype sequences, were
constructed as phased allelic HLA-B sequences. In general,
allelic imbalance after PCR amplification has been occa-
sionally observed. Evidently, this problem is not specific to
NGS analyses. If capture, NGS, or the analytical step are
causes of allelic imbalance, we would observe the discrep-
ancy between our NGS typing and SSO typing, which was
not the case in the current study. The current protocol
aimed at minimizing the disparity of each sample; this
was achieved although not perfectly. The minimum depth
could be important to obtain phase-defined sequences be-
cause lower depth could leave unphased region. However,
complete phase-defined sequencing is dependent on the
allelic type of the sample, thereby it is not easy to give an
exact depth number to accomplish the sequencing in
general. In the current study, the most important point of
the current study was to obtain complete phase-defined
Figure 1 Schematic workflow of BeNUS. The BeNUS method was constructed using two categories of method, size selection (A) and
normalization of DNA amount (B). (A) Size selection using altered AMPure XP beads. For size selection, two different bead ratio conditions were
applied according to DNA volume: 0.4× bead ratio for <1,000 bp fragment size and 0.5× bead ratio for >500 bp. After bead selection, DNA
fragments ranging from 500 to 1,000 bp were bound to the beads. (B) Normalization of DNA amount using altered AMPure XP beads DNA
fragments with target sizes ranging from 500 to 1,000 bp were selected for effective HLA gene haplotype phasing. The size selection and DNA
amount also defined an actual molar concentration for bridge PCR to generate clusters in a flow cell, because DNA fragments of over 1,000 bp
are not efficiently amplified. Only one bead reaction condition was applied to normalize the amount of DNA. This step enables a defined amount
of DNA to be bound to the diluted beads. This step enables a defined amount of DNA to be bound to the diluted beads.
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achieved using the current protocol.
After obtaining phase-defined HLA gene sequences
for 192 haplotype sequences, we attempted to assign
HLA allele numbers to these sequences by searching for
known allele sequences in the IMGT/HLA database. We
used phased HLA-B haplotype sequences that spanned
all of the intronic and exonic regions as queries against
genomic and CDS sequences in the database. The deter-
mined HLA-B allele calls in all samples were consistent
with PCR-SSO and Omixon Target, although the PCR-
SSO determined HLA allele numbers were limited to a
4-digit resolution.Conclusions
We established a simple, high-throughput, high-resolution,
and high-fidelity HLA sequencing and genotyping me-
thod, as a combination of the Nextera kit and our new
BeNUS method. We successfully applied our method
for HLA-B sequencing in 96 samples, without drop-
outs. By developing BeNUS, it becomes feasible to con-
struct multi-libraries without agarose gel size selection
and DNA density control of each library. This method
would be greatly advantageous for clinical applications
that require a user-friendly and cost-effective protocol,
with high throughput and accuracy. Our protocols
open a way to prepare NGS libraries for large-scale
Figure 3 Alignment view of heterozygous samples showing several SNVs or a single SNV between two HLA allele sequences in one
exon. The horizontal axis shows the position in HLA-B and red boxes at the top are exon regions. The vertical axis of upper graph in each sample
shows read depth at each position, and red and blue bars in lower region are aligned reads as read1 (red) and read2 (blue). In the read depth
graph, the gray color denotes bases identical with the reference genome, and, green, blue, orange, and red colors denote bases different from
reference genome as A, C, G and T, respectively. If a position has 2 colors, it means heterozygous SNV, meanwhile, 1 color at one position means
homozygous SNV. Red arrow indicates positions of the heterozygous SNVs.
Figure 2 Percentage of read numbers among 96 multiplexing indexes. The horizontal axis shows the 96 samples and the vertical axis shows
read percentage among demultiplexed 96 FASTQ files. Red bars show distribution of read number in proportion to libraries prepared by
BioAnalyzer and agarose gel size selection, and blue bars show result by BeNUS method. Sequence reads for each sample were counted for
evaluation of the normalization step in library preparation.
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Table 1 Alignment of the HLA-B sequence and genotype in 96 samples
Sample HLA-B SSO HLA-B PSP* Depth Note
Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2
0554 HLA-B*44:03 HLA-B*40:06 HLA-B*44:03:01:01 HLA-B*40:06:01:01 1543.4 1114.5
0555 HLA-B*40:01 HLA-B*44:03 HLA-B*40:01:02 HLA-B*44:03:01 2228.5 2084.8
0556 HLA-B*13:01 HLA-B*46:01 HLA-B*13:01:01 HLA-B*46:01:01 860.5 765
0560 HLA-B*13:01 HLA-B*51:01 HLA-B*13:01:01 HLA-B*51:01:01 1416.5 1455.9
0605 HLA-B*52:01 HLA-B*52:01 HLA-B*52:01:01:02 HLA-B*52:01:01:02 6928.7 Homozygous
0607 HLA-B*07:02 HLA-B*07:02 HLA-B*07:02:01 HLA-B*07:02:01 7357.3 Homozygous
0616 HLA-B*40:02 HLA-B*52:01 HLA-B*40:02:01 HLA-B*52:01:01:02 513.2 500.6
0639 HLA-B*40:06 HLA-B*35:01 HLA-B*40:06:01:01 HLA-B*35:01:01:02 1758 1656.8
0642 HLA-B*40:01 HLA-B*35:01 HLA-B*40:01:02 HLA-B*35:01:01:02 2016.8 1545.3
0645 HLA-B*54:01 HLA-B*54:01 HLA-B*54:01:01 HLA-B*54:01:01 6537 Homozygous
0649 HLA-B*55: 02 HLA-B*40:02 HLA-B*55:02:01 HLA-B*40:02:01 1402.3 1635.5
0652 HLA-B*15:01 HLA-B*35:01 HLA-B*15:01:01:01 HLA-B*35:01:01:02 2395.4 2308.4
0658 HLA-B*56:01 HLA-B*44:03 HLA-B*56:01:01 HLA-B*44:03:01 1686.7 2074
0663 HLA-B*13:01 HLA-B*52:01 HLA-B*13:01:01 HLA-B*52:01:01:02 1538.1 1455.7
0666 HLA-B*54:01 HLA-B*38:02 HLA-B*54:01:01 HLA-B*38:02:01 2105 1790.8
0703 HLA-B*55:02 HLA-B*40:06 HLA-B*55:02:01 HLA-B*40:06:01:01 1173.1 1445.3
0735 HLA-B*44:03 HLA-B*38:02 HLA-B*44:03:01 HLA-B*38:02:01 2507.5 1998.5
0739 HLA-B*40:02 HLA-B*48:01 HLA-B*40:02:01 HLA-B*48:01:01 1947.1 2382.9
0741 HLA-B*59:01 HLA-B*07:02 HLA-B*59:01:01:01 HLA-B*07:02:01 1458.6 2336
0772 HLA-B*07:02 HLA-B*48:01 HLA-B*07:02:01 HLA-B*48:01:01 3512.9 3425
0779 HLA-B*44:02 HLA-B*39:01 HLA-B*44:02:01:01 HLA-B*39:01:01:03 1677.5 1060.6
0784 HLA-B*40:06 HLA-B*15:01 HLA-B*40:06:01:01 HLA-B*15:01:01:01 1875.1 1820.8
0785 HLA-B*52:01 HLA-B*51:01 HLA-B*52:01:01:01 HLA-B*51:01:01 6041.4 6018.4 Onlu 4 heterozygous SNVs
0810 HLA-B*40:02 HLA-B*46:01 HLA-B*40:02:01 HLA-B*46:01:01 560.8 546.8
0815 HLA-B*35:01 HLA-B*07:02 HLA-B*35:01:01 HLA-B*07:02:01 1239.5 1740
0821 HLA-B*40:01 HLA-B*40:02 HLA-B*40:01:02 HLA-B*07:02:01 1239.5 1740
0821 HLA-B*40:01 HLA-B*40:02 HLA-B*40:01:02 HLA-B*40:02:01 2144.4 1925.5
0822 HLA-B*54:01 HLA-B*35:01 HLA-B*54:01:01 HLA-B*35:01:01 1550 1840.6
0823 HLA-B*15:11 HLA-B*07:02 HLA-B*15:11:01 HLA-B*07:02:01 703.5 914.6
0830 HLA-B*51:01 HLA-B*48:01 HLA-B*51:01:01 HLA-B*48:01:01 1833.8 2509
0969 HLA-B*40:06 HLA-B*51:01 HLA-B*40:06:01:01 HLA-B*51:01:01 1575.4 1650.4
0975 HLA-B*44:03 HLA-B*07:02 HLA-B*44:03:01 HLA-B*07:02:01 180.4 209.3
0976 HLA-B*54:01 HLA-B*35:01 HLA-B*54:01:01 HLA-B*35:01:01 3635.9 3759.2
0977 HLA-B*44:02 HLA-B*15:18 HLA-B*44:02:01:01 HLA-B*15:18:01 722.2 574.4
0979 HLA-B*39:01 HLA-B*39:01 HLA-B*39:01:01:03 HLA-B*39:01:03 2128 2125.7 Only 1 heterozygous SNV
0991 HLA-B*15:01 HLA-B*39:01 HLA-B*15:01:01 HLA-B*39:01:01:03 1685.4 1551.3
0997 HLA-B*15:01 HLA-B*51:01 HLA-B*15:01:01:01 HLA-B*39:01:01:03 1685.4 1551.3
0997 HLA-B*15:01 HLA-B*51:01 HLA-B*15:01:01 HLA-B*51:01:01 2588 2692.1
0999 HLA-B*48:01 HLA-B*39:01 HLA-B*48:01:01 HLA-B*39:01:01:03 1470.4 1045.3
1009 HLA-B*54:01 HLA-B*39:01 HLA-B*54:01:01 HLA-B*39:01:01:03 326.8 294.7
1011 HLA-B*52:01 HLA-B*07:02 HLA-B*52:01:01:02 HLA-B*07:02:01 730.9 943.7
1012 HLA-B*35:01 HLA-B*48:01 HLA-B*35:01:01:02 HLA-B*48:01:01 1830.1 2482.1
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Table 1 Alignment of the HLA-B sequence and genotype in 96 samples (Continued)
1013 HLA-B*54:01 HLA-B*52:01 HLA-B*54:01:01 HLA-B*52:01:01:02 533.9 600.7
1014 HLA-B*55:02 HLA-B*51:01 HLA-B*55:02:01 HLA-B*51:01:01 970.1 1153.1
1016 HLA-B*44:03 HLA-B*35:01 HLA-B*44:03:01 HLA-B*35:01:01 739.7 655.5
1018 HLA-B*46:01 HLA-B*15:01 HLA-B*46:01:01 HLA-B*15:01:01:01 5360.8 5496.1 Only 7 heterozygous SNVs
1030 HLA-B*40:06 HLA-B*07:02 HLA-B*40:06:01:01 HLA-B*07:02:01 1638.8 2668.6
1045 HLA-B*15:11 HLA-B*35:01 HLA-B*15:11:01 HLA-B*35:01:01:02 1597.5 1448.8
1056 HLA-B*58:01 HLA-B*67:01 HLA-B*58:01:01 HLA-B*67:01:01 2497.9 2214.5
1057 HLA-B*40:02 HLA-B*40:02 HLA-B*40:02:01 HLA-B*40:02:01 4113.6 Homozygous
1064 HLA-B*40:06 HLA-B*51:01 HLA-B*40:06:01:01 HLA-B*51:01:01 963.5 1048.8
1065 HLA-B*54:01 HLA-B*52:01 HLA-B*54:01:01 HLA-B*52:01:01:02 1213.9 1563.8
1071 HLA-B*56:01 HLA-B*40:06 HLA-B*56:01:01 HLA-B*40:06:01:01 4061.2 1223
1079 HLA-B*40:02 HLA-B*39:01 HLA-B*40:02:01 HLA-B*39:01:03 2319.8 1507.5
1082 HLA-B*40:01 HLA-B*51:01 HLA-B*40:01:02 HLA-B*51:01:01 639.3 542.7
1083 HLA-B*59:01 HLA-B*54:01 HLA-B*59:01:01 HLA-B*54:01:01 716.5 1208.2
1087 HLA-B*44:03 HLA-B*07:02 HLA-B*44:03:01 HLA-B*07;02:01 1975.5 2605.1
1095 HLA-B*40:02 HLA-B*54:01 HLA-B*40:02:01 HLA-B*51:01:01 946.4 962.2
1097 HLA-B*40:01 HLA-B*40:06 HLA-B*40:01:02 HLA-B*40:06:01:01 2642.2 1822.5
1110 HLA-B*40:01 HLA-B*51:01 HLA-B*40:01:02 HLA-B*51:01:01 1277.1 1156.9
1111 HLA-B*54:01 HLA-B*40:03 HLA-B*54:01:01 HLA-B*40:03 831.3 943.7
1116 HLA-B*52:01 HLA-B*07:02 HLA-B*52:01:01:02 HLA-B*07:02:01 981.1 1535.6
1117 HLA-B*52:01 HLA-B*51:01 HLA-B*52:01:01:02 HLA-B*51:01:01 5900.6 6084.9 Only 3 heterozygous SNVs
1119 HLA-B*35:01 HLA-B*07:02 HLA-B*35:01:01:02 HLA-B*07:02:01 921.3 1370.1
1129 HLA-B*59:01 HLA-B*40:02 HLA-B*59:01:01:01 HLA-B*40:02:01 1472.9 2178.5
1131 HLA-B*44:03 HLA-B*52:01 HLA-B*44:03:01 HLA-B*52:01:01:02 1519.9 1456.8
1142 HLA-B*40:02 HLA-B*39:04 HLA-B*40:02:01 HLA-B*39:04 1253 886.5
1144 HLA-B*44:03 HLA-B*15:11 HLA-B*44:03:01 HLA-B*15:11:01 1061.7 993.2
1149 HLA-B*44:03 HLA-B*52:01 HLA-B*44:03:01 HLA-B*52:01:01:02 719.6 633.6
1154 HLA-B*59:01 HLA-B*40:02 HLA-B*59;01:01:01 HLA-B*40:02:01 146.2 171.8
1157 HLA-B*35:01 HLA-B*48:01 HLA-B*35:01:01:02 HLA-B*48:01:01 911 1077.3
1160 HLA-B*59:01 HLA-B*54:01 HLA-B*59:01:01:02 HLA-B*54:01:01 129.8 166.8
1161 HLA-B*55:02 HLA-B*51:01 HLA-B*55:02:01 HLA-B*51:01:01 402.5 366.6
1163 HLA-B*56:01 HLA-B*46:01 HLA-B*56:01:01 HLA-B*46:01:01 2048.1 2276.5
1165 HLA-B*15:01 HLA-B*07:02 HLA-B*15:01:01:01 HLA-B*07:02:01 688.1 907.3
1167 HLA-B*40:06 HLA-B*52:01 HLA-B*40:06:01:01 HLA-B*52:01:01:02 1486.7 4508.1
1169 HLA-B*54:01 HLA-B*54:01 HLA-B*54:01:01 HLA-B*54:01:01 7086.1 Homozygous
1171 HLA-B*54:01 HLA-B*44:03 HLA-B*54:01:01 HLA-B*44:03:01 1586.6 1833.9
1175 HLA-B*15:11 HLA-B*15:01 HLA-B*15:11:01 HLA-B*HLA-B*15:01::01:01 5717.6 5693 Only 3 heterozygous SNVs
1182 HLA-B*55:02 HLA-B*51:01 HLA-B*55:02:01 HLA-B*51:01:01 1156.6 1451.5
1183 HLA-B*54:01 HLA-B*35:01 HLA-B*54:01:01 HLA-B*35:01:01 1413.5 1537.7
1184 HLA-B*52:01 HLA-B*52:01 HLA-B*52:01:01:02 HLA-B*52:01:01:02 6701.3 Homozygous
1199 HLA-B*51:01 HLA-B*51:01 HLA-B*51:01:01 HLA-B*51:01:01 5229.1 Homozygous
1201 HLA-B*44:03 HLA-B*52:01 HLA-B*44:03:01 HLA-B*52:01:01:02 1990.6 1665.9
1203 HLA-B*54:01 HLA-B*52:01 HLA-B*54:01:01 HLA-B*52:01:01:02 1246.4 1313.2
1217 HLA-B*40:01 HLA-B*46:01 HLA-B*40:01:02 HLA-B*46:01:01 2225.1 1882.2
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Table 1 Alignment of the HLA-B sequence and genotype in 96 samples (Continued)
1224 HLA-B*40:02 HLA-B*40:03 HLA-B*40:02:01 HLA-B*40:03 6306.5 6286.4 Only 3 heterozygous SNVs
1225 HLA-B*40:01 HLA-B*44:03 HLA-B*40:01:02 HLA-B*44:03:01 1554 1399.6
1229 HLA-B*52:01 HLA-B*52:01 HLA-B*52:01:01:02 HLA-B*52:01:01:02 6748.5 Homozygous
1234 HLA-B*44:03 HLA-B*40:06 HLA-B*44:03:01 HLA-B*40:06:01:01 2490.3 1715.9
1236 HLA-B*54:01 HLA-B*40:06 HLA-B*54:01:01 HLA-B*40:06:01:01 1132.4 1244.4
1238 HLA-B*40:02 HLA-B*67:01 HLA-B*40:02:01 HLA-B*67:01:01 2040.9 1691
1239 HLA-B*40:03 HLA-B*51:01 HLA-B*40:03 HLA-B*51:01:01 1787 1789.8
1250 HLA-B*44:03 HLA-B*51:01 HLA-B*44:03:01 HLA-B*51:01:01 357.7 317.8
1259 HLA-B*40:02 HLA-B*07:02 HLA-B*40:02:01 HLA-B*07:02:01 1346.9 1934.4
1260 HLA-B*40:06 HLA-B*35:01 HLA-B*40:06:01:01 HLA-B*35:01:01:02 641.9 680.8
1265 HLA-B*40:01 HLA-B*40:06 HLA-B*40:01:02 HLA-B*40:06:01:01 2226.2 1691.7
*Phase defined sequencing pipeline.
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A total of 96 unrelated healthy Japanese control subjects
were recruited at the Health Evaluation and Promotion Cen-
ter of Tokai University Hospital. All subjects gave written in-
formed consent for the study. Ethical approvals for this
study protocol were obtained from the IRBs of National In-
stitute of Genetics and Tokai University School of Medicine.
DNA samples
DNA samples were extracted from peripheral blood using
a DNA extraction kit Genomix (Biologica, Nagoya, Japan)
using the manufacturer’s instructions.
HLA genotyping with PCR-SSO method
We genotyped HLA-B using the Luminex assay system and
HLA typing kits (WAKFlow HLA Typing kits, Wakunaga,
Osaka, Japan or LABType SSO, One Lambda, Canoga
Park, CA, USA).
Library preparation
HLA-B was amplified using locus-specific primers by
long-range PCR [1]. Each amplification reaction contained
20 ng of genomic DNA, 0.25 unit of PrimeSTAR® GXL
DNA polymerase (TAKARA BIO Inc., Shiga, Japan), 1×
PrimeSTAR® GXL buffer (Mg2+ concentration 1 mM),
0.2 mM of each dNTP, and 0.2 μM of each primer in a
10 μl reaction volume. Cycling parameters were as follows:
initial denaturation of 94°C for 2 min followed by 30 cycles
of 98°C for 10 s, 60°C for 15 s, and 68°C for 5 min. Each
PCR product concentration was measured with a Qubit
dsDNA BR Assay Kit (Life Technologies, Carlsbad, CA,
USA). PCR products were subjected to library preparationwith a Nextera DNA Sample Preparation Kit (Illumina,
San Diego, CA, USA) and a KAPA Library Amplification
kit (Kapa Biosystems, Inc., Wilmington, MA, USA). The
KAPA kit was used for library amplification because of its
advantage of coverage depth in high-GC-content regions
during library amplification (Additional file 5: Figure S5).
Each sample was dual indexed and normalized with modi-
fied AMPure XP beads (Beckman Coulter Inc., Brea, CA,
USA) method, which include optimal size selection and
normalization of DNA concentration (Figure 1).
BeNUS for 96-well plate-based library
We prepared altered AMPure XP beads by resuspend-
ing the beads in half of the original volume of 20% poly-
ethylene glycol 8000 (PEG) and 2.5 M NaCl solution.
The resuspended beads were twice as concentrated as the
standard AMPure XP beads (Additional file 6: Figure S6).
The optimal volume ratio of altered beads to DNA solu-
tion was determined by relation between the PEG–NaCl
concentration and the selected DNA fragment size
(Additional file 6: Figure S6). For library size selection,
20 μl of resuspended altered beads was added to 50 μl of
diluted library (5 μl of PCR product and 45 μl of water),
mixed well by pipetting at least 10 times, and incubated
for 5 min at room temperature. The tube was placed on
the NGS MagnaStand (NIPPON Genetics, Tokyo, Japan)
to separate the beads from the supernatant. After separ-
ation, the supernatant was carefully transferred to a new
tube. Five μl of the altered beads were added to the super-
natant, mixed, and incubated, and the beads were then
separated from the supernatant on the same conditions.
The supernatant containing unwanted DNA was carefully
removed. One hundred μl of 80% ethanol was added to
the tube for washing and the supernatant was carefully
discarded after incubation and separation. The beads were
air-dried for 10 min while the tube was on the magnetic
Hosomichi et al. BMC Genomics 2014, 15:645 Page 8 of 9
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the beads into 22 μl of water (Figure 1). Next, to normalize
DNA concentration, altered beads, which were diluted
20 fold with 20% PEG and 2.5 M NaCl solution, were used
to capture a certain amount of DNA (Additional file 2:
Figure S2). Twenty μl of 20-fold diluted altered beads and
20 μl of isopropanol were added to the 20 μl of size-
selected library, mixed well by pipetting at least 10 times,
and incubated for 5 min at room temperature. The tube
was placed on the magnetic stand to separate the beads
from the supernatant. After the supernatant was dis-
carded, 100 μl of 80% ethanol was added to the tube kept
on the magnetic stand and incubated at room temperature
for 30 s, and then the supernatant was carefully discarded.
The beads were air-dried, and then 20 μl of water was
added to elute the normalized libraries (Figure 1). The
combination of fragment size selection and normalization
of DNA amount results in an equalized DNA molar con-
centration among 96 libraries.
Sequencing
Equal volumes of libraries were pooled and subjected to
multiplex sequencing on the MiSeq sequencer (Illumina).
The MiSeq flow cell of 2 × 300 bp paired-end reads re-
sulted in 11.6 million read pairs corresponding to 6 Gbp
of valid sequence data without adapter sequence.
Determination of the HLA-B sequence
Sequence reads were distributed according to index in-
formation to assign samples. We used the phase-defined
sequencing pipeline (http://p-galaxy.ddbj.nig.ac.jp) [1,10],
which include trimming low quality bases (Phred quality
score < Q20), selection of only long (>200 bp) paired-end
reads, alignment to reference sequence, SNVs and indel
identification, and haplotype phasing. HLA-B sequence
(UCSC hg19, chr6: 31,317,316 – 31,331,864, complement)
was used as reference sequence. After phasing, two BAM
files were created as phased HLA-B alignments. The IGV
genome viewer [11] was used to visualize the alignment
results. The consensus sequences in FASTQ or FASTA
format were constructed for searching the IMGT/HLA
(http://www.ebi.ac.uk/imgt/hla/) database to identify the
HLA alleles. We used them as query for BLAT [12] search
to known HLA allele sequences in the database as com-
plete matches of genomic sequence or CDS sequence. For
validation, HLA-B genotype calls were compared with
the result of PCR-SSO and Omixon Target HLA Typing
(Omixon Inc., Budapest, Hungary) [13,14].
Availability of supporting data
The data set associated with this project has been sub-
mitted to DDBJ Sequence Reads Archive (DRA acces-
sion number: DRA001289).Additional files
Additional file 1: Figure S1. Fragment size selection focusing on the
500–1,000 bp size range.
Additional file 2: Figure S2. Association between number of beads
and bound DNA for normalization of DNA concentration.
Additional file 3: Figure S3. Effect of DNA normalization as confirmed
by BioAnalyzer.
Additional file 4: Figure S4. Example of partial phasing for a specific exon.
Additional file 5: Figure S5. KAPA Library Amplification kit showing
high coverage in a high-GC-content region.
Additional file 6: Figure S6. Method for preparation of beads and
optimal bead volume in the DNA solution.
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